|
Orthopedic Oncologist Hones Bone Website
By Elizabeth Hofheinz (posted April 9, 2008)
The navigation of education is now easier…orthopedic oncologist James C. Wittig, M.D., the new Chief of Orthopedic Oncology (Pediatric & Adult) and Associate Professor of Orthopedic Surgery at Mount Sinai Medical Center, has redesigned his website to provide more educational and user-friendly resources for the field of orthopedic oncology.
New Fixation Systems for Rotary Cuff and ALC Repair From DePuy Mitek
By Walter Eisner (posted March 24, 2008)
In another sign that the DePuy Orthopaedics franchise was busy at AAOS, DePuy Mitek launched the HEALIX™ PEEK Suture Anchor System for arthroscopic rotator cuff repair and the Femoral INTRAFIX™ ACL Fixation System for ACL repair using the anteromedial (AM) approach.
DePuy Orthopaedics Rattles Off New Product Announcements at AAOS
By Walter Eisner (posted March 21, 2008)
DePuy Orthopaedics was busy at AAOS this year, making numerous announcements about new product launches and company initiatives.
Them Travelin' Bones: Some stories are just fun to report.
By Walter Eisner (posted March 14, 2008)
Don't try to sneak bones through the airport in Munich. According to a March 12 AP report, an Italian woman tried to get her brother's skeleton through the Munich airport after arriving on a flight from Brazil.
Watson Will Launch Generic Fosamax®
By Elizabeth Hofheinz (posted February 8, 2008)
Good news for patients’ bones and wallets. Watson Pharmaceuticals, Inc. has announced that as of close of business February 6, 2008, when Fosamax® loses its market exclusivity, the company will begin shipping alendronate sodium in the 35 mg and 70 mg once weekly dosage strengths.
FDA Approves Chinese Hamster Ovary Cells as Clotting Solution
By Walter Eisner (posted January 18, 2008)
The FDA has just approved the first clotting solution manufactured using recombinant DNA techniques. The approved indication is to help stop small blood vessels from bleeding after surgery.
Syndicom Launches Online Medical Community for Orthopedic Trauma
By Elizabeth Hofheinz (posted October 31, 2007)
Syndicom, a provider of problem-solving Web-based tools for medical professionals, medical device manufacturers, and other professional communities, announced the launch of TraumaConnect. A free Web-based service, TraumaConnect is modeled on the Syndicom SpineConnect community, which now boasts more than 900 spine surgeon members.
Data in on Stem Cells for Long Bone Non-Union Fracture Phase I/II Study
By Robin Young (posted October 29, 2007)
At last week’s Orthopedic Trauma Association meeting in Boston, Aastrom Biosciences, Inc. released final results from its Phase I/II stem cell study for long bone non-union fractures. Matthew L. Jimenez, M.D. of the Illinois Bone and Joint Institute is lead investigator.
New Technology for Bone Fracture Screening
By Elizabeth Hofheinz (posted September 28, 2007)
Here’s a new bone-testing device that offers prediction with conviction. The Canadian company Cooler Solutions, which specializes in health and wellness solutions, has developed a new technology that has the potential to revolutionize bone fracture risk assessment.
Wyeth Presents Fracture Data for Investigational Osteoporosis Therapy
By Elizabeth Hofheinz (posted September 21, 2007)
“Significantly reduced”: Those are the words you want to hear if you are researching osteoporosis medication. This week, a certain drug manufacturer delivered on that hope.
New Bioreplacable Suture Anchors Introduced by DePuy Mitek
By Walter Eisner (posted September 21, 2007)
A sudden injury or overuse of the shoulder ligament can result in shoulder instability. Athletes and active people who are involved in high-contact or overhead sports are particularly susceptible to such injury. For those patients, DePuy Mitek has announced the launch of LUPINE™ BR and BIOKNOTLESS™ BR, the first suture anchors made from DePuy Mitek’s proprietary Biocryl Rapide biocomposite material.
First Osteoporosis Study in Hip Fracture Finds Reclast® Prevents Additional Fractures and Improves Survival
By Elizabeth Hofheinz (posted September 20, 2007)
Breaking the hold of hip fractures … Novartis Pharmaceuticals announces the results of the first-ever clinical study in osteoporosis patients who have had a hip fracture. The study shows that a once-yearly infusion of Reclast® (zoledronic acid) injection reduced the risk of subsequent fractures by 35% compared to placebo.
Reclast® Gets FDA Approval for Women With Postmenopausal Osteoporosis
By Elizabeth Hofheinz (posted August 23, 2007)
Maybe patients can set a reminder to take it when they pay their taxes ... or on the first day of summer. Their osteoporosis medication, that is. Novartis has announced that the once-yearly medication Reclast® (zoledronic acid), an injectable medication, has been approved by the FDA as the first and only once-yearly medicine for postmenopausal osteoporosis. While oral bisphosphonate therapies have to be taken daily, weekly, or monthly, Reclast is taken once annually.
Study of Low-Dose Fluoride to Fight Osteoporosis
By Elizabeth Hofheinz (posted August 17, 2007)
According to recent work published in The Journal of Clinical Endocrinology & Metabolism (Vol. 92, No. 7 2446-2452, July 2007), adding low doses of fluoride to estrogen therapy may fight osteoporosis in postmenopausal women. But there are cautions.
Men and the Cost-Effectiveness of Osteoporosis Screening, Treatment
By Elizabeth Hofheinz (posted August 10, 2007)
According to the Journal of the American Medical Association, a study published in its August 8, 2007, edition has found that it may be cost-effective to screen and treat selected older men with osteoporosis, depending on their age and if they have had a prior fracture.
Stryker to Offer Medical-Grade Video
By Walter Eisner (posted August 6, 2007)
Stryker Communications and Rivulet Communications have entered into an agreement whereby the Stryker unit will resell Rivulet's internet protocol (IP) video networking products.
DePuy Offers New Product for Hip Fracture Treatment
By Walter Eisner (posted July 27, 2007)
DePuy Orthopaedics has announced the launch of the Peak FX™ Hip Plate System. The system allows for the use of minimally invasive procedures during surgery for the treatment of nearly 200,000 patients who suffer from intertrochanteric hip fractures in the United States each year, according to the company announcement.
Dong Wha and Procter & Gamble Pharmaceuticals Pair Up for Osteoporosis Treatment
By Elizabeth Hofheinz (posted July 5, 2007)
According to PRNewswire, Korean company Dong Wha Pharmaceutical Ind. Co. and Procter & Gamble Pharmaceuticals Inc. (P&GP) have announced a strategic alliance whereby P&GP will have rights to develop and commercialize a novel class of molecules for the treatment of osteoporosis.
|